FDA sched­ules ad­comms for En­ta­sis' an­timi­cro­bial treat­ment, In­ter­cep­t's NASH hope­ful

The FDA this morn­ing an­nounced two up­com­ing ad­vi­so­ry com­mit­tee meet­ings in April and May — with the goal of re­view­ing two drugs with a lot of his­to­ry that have gone through mul­ti­ple set­backs.

Ac­cord­ing to no­tices pub­lished in the Fed­er­al Reg­is­ter, the FDA is con­ven­ing its An­timi­cro­bial Drugs Ad­vi­so­ry Com­mit­tee on April 17 to dis­cuss En­ta­sis Ther­a­peu­tics’ NDA for sul­bac­tam-dur­lobac­tam for the treat­ment of Acine­to­bac­ter in­fec­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER